First OTC Low-Dose Brimonidine Eye Drop Approved for Ocular Redness

Share this content:

The Food and Drug Administration (FDA) has approved Lumify 0.025%, the first over-the-counter low-dose brimonidine tartrate ophthalmic solution for the treatment of ocular redness. 

Brimonidine, a selective alpha-2 adrenergic receptor agonist, works by selectively constricting the veins in the eye, increasing the availability of oxygen to surrounding tissue and reducing the likelihood of rebound redness, often associated with non-selective redness reducers. In clinical studies, low-dose brimonidine showed 95% symptom improvement at 1 minute, and reduced redness for up to 8 hours. 

Brimonidine is already approved in higher doses as a prescription eye drop for the treatment of intraocular pressure reduction in glaucoma patients.

Lumify is expected to be available from Bausch + Lomb in the second quarter of 2018.

For more information visit Bausch.com.

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »